OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

Overactive bladder affects 12% to 17% of the general population and almost a third experience urinary incontinence, which may severely impact health related quality of life. Oral anticholinergics are the mainstay of pharmacological treatment but they are limited by inadequate efficacy or side effect...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Journal of urology Ročník 197; číslo 2S; s. S216
Hlavní autoři:	Nitti, Victor W, Dmochowski, Roger, Herschorn, Sender, Sand, Peter, Thompson, Catherine, Nardo, Christopher, Yan, Xiaohong, Haag-Molkenteller, Cornelia
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.02.2017
Témata:	Acetylcholine Release Inhibitors - administration & dosage Acetylcholine Release Inhibitors - adverse effects Aged Botulinum Toxins, Type A - administration & dosage Botulinum Toxins, Type A - adverse effects Cholinergic Antagonists - therapeutic use Female Humans Injections, Intramuscular Male Middle Aged Neuromuscular Agents - administration & dosage Neuromuscular Agents - adverse effects Urinary Bladder - drug effects Urinary Bladder, Overactive - complications Urinary Bladder, Overactive - drug therapy Urinary Incontinence - drug therapy Urinary Incontinence - etiology Urinary Retention - chemically induced Urinary Tract Infections - chemically induced injections overactive urinary bladder intramuscular botulinum toxins onabotulinumtoxinA urinary incontinence
ISSN:	1527-3792, 1527-3792
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!